Drug intelligence / Profile preview

dupilumab + itepekimab

Development stage: Unknown
Lead developer: Sanofi
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

Dupilumab + itepekimab is a combination therapy being investigated for respiratory conditions. Dupilumab is a fully human monoclonal antibody that inhibits the signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways, which are key drivers of type 2 inflammation. Itepekimab is a novel human IgG4P monoclonal antibody that targets interleukin-33 (IL-33), a proinflammatory alarmin cytokine that initiates and amplifies both type 1 and type 2 inflammatory cascades. The combination has been studied in clinical trials for asthma and is being investigated for chronic obstructive pulmonary disease (COPD).

Brand names: Dupixent
Other names: itepekimab

Targets

IL4R (Interleukin-4 receptor alpha subunit)IL33 (IL-33)

Beyond the preview

Go deeper on dupilumab + itepekimab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on dupilumab + itepekimab.

Explore the full profile